Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
Open Access
- 1 January 2011
- journal article
- Published by Hindawi Limited in Parkinson's Disease
- Vol. 2011, 1-14
Abstract
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γagonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γagonists have received increasing attention for their neuroprotective properties displayed in a variety of neurodegenerative diseases, including Parkinson's disease (PD), likely related to the anti-infammatory activity of these compounds. Recent studies indicate that neuroinflammation, specifically reactive microglia, plays important roles in PD pathogenesis. Moreover, after the discovery of infiltrating activated Limphocytes in the substantia nigra (SN) of PD patients, most recent research supports a role of immune-mediated mechanisms in the pathological process leading to chronic neuroinflammation and dopaminergic degeneration. PPAR-γare highly expressed in cells of both central and peripheral immune systems, playing a pivotal role in microglial activation as well as in monocytes and T cells differentiation, in which they act as key regulators of immune responses. Here, we review preclinical evidences of PPAR-γ-induced neuroprotection in experimental PD models and highlight relative anti-inflammatory mechanisms involving either central or peripheral immunomodulatory activity. Specific targeting of immune functions contributing to neuroinflammation either directly (central) or indirectly (peripheral) may represent a novel therapeutic approach for disease modifying therapies in PD.Keywords
This publication has 125 references indexed in Scilit:
- The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell–intrinsic fashion and suppresses CNS autoimmunityJournal of Experimental Medicine, 2009
- Th17 cells: from precursors to players in inflammation and infectionInternational Immunology, 2009
- Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's diseaseBrain, 2008
- The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase BBritish Journal of Pharmacology, 2008
- Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague–Dawley ratsNeuroscience Letters, 2008
- PPARs and molecular mechanisms of transrepressionBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Non-steroidal anti-inflammatory drugs in Parkinson's diseaseExperimental Neurology, 2007
- Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson’s diseaseNeuroscience, 2007
- Systemic LPS causes chronic neuroinflammation and progressive neurodegenerationGlia, 2007
- A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γNature, 2005